Bengaluru-based Remidio Innovative Solutions, a pioneer in AI-driven ophthalmic technology, has introduced Neubo 130, a next-generation ultra-widefield neonatal retinal imaging system. Designed to enhance precision diagnostics for Retinopathy of Prematurity (ROP), the system redefines neonatal eye screening through advanced optics and real-time edge AI capabilities.
Addressing India’s Growing Need for Neonatal Eye Screening
India records over three million premature births annually, leading to nearly 15 million retinal examinations if every infant is screened as per medical protocols. However, the country faces a significant shortage of ROP specialists. To close this gap, Remidio’s Neubo 130 leverages engineering innovation to deliver timely, accurate, and accessible retinal imaging—empowering healthcare providers to conduct bedside screening without dependence on internet connectivity.
Revolutionary Design for Precision and Ease of Use
Built for clinicians operating in hospitals and neonatal intensive care units (NICUs), Neubo 130 integrates innovative optical engineering with edge-based AI to detect ROP in real time. Its 130° field of view, through-the-lens illumination, and light-shaping technology ensure uniform retinal brightness and high-quality peripheral visualization—essential for identifying subtle retinal changes that influence treatment outcomes.
Key Highlights of Neubo 130
- Consistent Peripheral Detail: Uniform illumination minimizes glare, ensuring clear peripheral imaging.
- Small-Pupil Imaging: Delivers high-quality images even with pupils as small as 3 mm.
- Instant, Private Bedside Triage: Offline AI assists in detecting ROP and plus disease, while standardized workflows reduce missed cases.
- Panoramic Views with Fewer Retakes: Auto-montage aligns multiple gazes into a seamless 130° composite image.
- Collaborative Care-Ready: Fully compatible with telemedicine and cloud platforms for secure review, triage, and referrals.
Transforming Neonatal Eye Care Through Technology
“The launch of Neubo 130 marks a major step forward in neonatal eye care,” said Dr. Anand Sivaraman, CEO of Remidio. “This platform reframes ROP from a resource problem to an engineering solution. By enabling dependable, on-the-spot decisions at the bedside, we move from ‘screening when possible’ to ‘protecting vision as standard.’”
Lightweight, Scalable, and Accessible Innovation
As reported by Business Standard, weighing under 500 grams and equipped with a 2.4 MP high-resolution sensor, Neubo 130 delivers robust imaging in a portable design. Its offline AI workflow ensures secure, real-time analysis, making it suitable for diverse healthcare settings—from tertiary hospitals to Special Newborn Care Units (SNCUs).
Through Neubo 130, Remidio reinforces its mission to make eye care accessible, affordable, and scalable, bridging the gap between advanced technology and neonatal vision preservation.